IN THE SPOTLIGHT

Advances in NSCLC Bring Excitement in the Lung Space; According to Jorge Nieva, MD, there are a multitude of things that can be explored to...

Advances in NSCLC Bring Excitement in the Lung Space; According to Jorge Nieva, MD, there are a multitude of things that can be explored to...

Radiomic Analysis and Liquid Biopsy in Preoperative CT of NSCLC: An Explorative Experience

Radiomic Analysis and Liquid Biopsy in Preoperative CT of NSCLC: An Explorative Experience

Taletrectinib Shows Positive Efficacy and Toxicity in ROS1+ NSCLC

Taletrectinib Shows Positive Efficacy and Toxicity in ROS1+ NSCLC

COCOON Shows How Prophylactic AE Management Boosts QOL When Treating NSCLC With Amivantamab Plus Lazertinib

COCOON Shows How Prophylactic AE Management Boosts QOL When Treating NSCLC With Amivantamab Plus Lazertinib

Therapeutic patterns and outcomes in older patients (aged ≥ 65 years) with stage III inoperable non-small cell lung cancer (NSCLC): An investigational study from the SEER database

Therapeutic patterns and outcomes in older patients (aged ≥ 65 years) with stage III inoperable non-small cell lung cancer (NSCLC): An investigational study from the SEER database

Taletrectinib is Suitable for First- and Second-Line ROS1+ NSCLC

Taletrectinib is Suitable for First- and Second-Line ROS1+ NSCLC

PD-L1 Expression and Comprehensive Genomic Profiling in Advanced NSCLC: A Single-Centre Experience

PD-L1 Expression and Comprehensive Genomic Profiling in Advanced NSCLC: A Single-Centre Experience

China NMPA Approves Savolitinib Plus Osimertinib for EGFR-Mutant, MET-Amplified NSCLC

China NMPA Approves Savolitinib Plus Osimertinib for EGFR-Mutant, MET-Amplified NSCLC

TTF-1 Negativity Predicts Poor Outcomes in Advanced Non-Squamous NSCLC Also in the Immunotherapy Era: A Multicenter Cohort Study and Meta-Analysis

TTF-1 Negativity Predicts Poor Outcomes in Advanced Non-Squamous NSCLC Also in the Immunotherapy Era: A Multicenter Cohort Study and Meta-Analysis

Zidesamtinib Produces Durable Responses in TKI-Pretreated, ROS1+ NSCLC

Zidesamtinib Produces Durable Responses in TKI-Pretreated, ROS1+ NSCLC